Fundus of patient with retinitis pigmentosa, mid stage. Credit: Hamel; licensee BioMed Central Ltd.

Applied Genetic Technologies (AGTC) has enrolled the first patient of the second cohort in a Phase l/ll clinical trial to examine the safety and efficacy of an unnamed investigational AAV-based gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP).

The open-label, dose-escalation trial is being conducted as part of a collaboration between AGTC and Biogen.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the collaboration, AGTC will receive a milestone payment of $10m from Biogen.

AGTC president and CEO Sue Washer said: “We are pleased to announce this important milestone under our collaboration with Biogen and remain on track to complete the dose-escalation portion of the trial in the first quarter of 2019.”

The Phase l/ll trial aims to evaluate the safety and efficacy of subretinal administration of the AAV-based gene therapy in patients diagnosed with XLRP caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene.

“The trial’s primary focus is to assess the safety of the vector and subretinal delivery procedure by analysing focal (ocular) and systemic treatment-emergent adverse events.”

The trial’s primary focus is to assess the safety of the vector and subretinal delivery procedure by analysing focal (ocular) and systemic treatment-emergent adverse events.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is also expected to measure biologic activity by assessing changes in visual function, retinal structure and quality of life.

Topline six-month data from the trial is expected to be released by the end of this year, with primary analysis of the full 12 month active trial data planned to be provided after six months.

XLRP is an inherited condition that gradually causes loss of vision in boys and young men.

The disease is characterised by night blindness in early childhood and progressive constriction of the visual field.